High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
Some patients undergoing radiotherapy for cancers of the head, neck, and brain are at risk for endocrinopathies. This article reviews the risks, detection, and management of radiotherapy-induced hypopituitarism.
Sexual dysfunction is a common and distressing side effect of prostate cancer treatment. Two new reports from randomized clinical trials offer mixed results for adjuvant pharmacotherapy intended to prevent erectile dysfunction in men undergoing radiotherapy for prostate cancer.
Although uncommon, this side effect of radiation with adjuvant drug therapy is unpredictable, sometimes delayed, and can occur with administration of antibiotics and other drugs as well as chemotherapy.
Soy and soy isoflavones are alleviating skin and lung toxicities from thoracic radiotherapy in preclinical study models; however, researchers stress the need for further studies.
Respiratory motion management reduces radiation exposure to nontarget tissues in patients undergoing treatment of cancers in the chest and abdomen.
These tools can help clinicians determine which treatments are ideal and explain to patients what their best options are and why.
Management of bone metastasis is an increasingly common challenge. Palliative radiotherapy is proving to effectively relieve pain and improve quality of life for patients.
Few patients with HCC are candidates for curative treatment at diagnosis. However, a new study demonstrated that stereotactic body radiotherapy...
The key to managing this late effect is patient education because it can manifest long after patients complete radiotherapy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|